BioNTech SE - ADR

+2.00 (+1.63%)
7:55:08 PM EDT: $124.98 +0.41 (+0.33%)

BioNTech And Pfizer: Additional Data From Phase 1/2 Trial With Bnt162b2

Published: 12/14/2020 11:09 GMT
BioNTech SE - ADR (BNTX) - Pfizer and Biontech Provide Data From German Phase 1/2 Study Further Characterizing Immune Response Following Immunization With Lead Covid-19 Vaccine Candidate Bnt162b2.
Study Results Demonstrate That Bnt162b2 Elicits a Combined Adaptive Humoral and Cellular Immune Response Against Sars-cov-2 and Provide Insights Into Composite Nature of Bnt162b2-induced T Cell Immunity.
Data Confirm Previous Findings From U.S. Trial Demonstrating a Good Safety Profile and Robust Induction of Antibody Responses With a Longer Follow-up Period of 85 Days.